An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Vehicle Controlled, Parallel Groups, Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of a 180 μg/ml Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Trial Profile

An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Vehicle Controlled, Parallel Groups, Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of a 180 μg/ml Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Glaucoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Cenegermin (Primary)
  • Indications Glaucoma
  • Focus Therapeutic Use
  • Acronyms NGF-Glaucoma
  • Sponsors Dompe Farmaceutici
  • Most Recent Events

    • 23 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.
    • 23 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top